middle.news
Amplia Therapeutics Scores Rare Second Complete Response in Pancreatic Cancer Trial
8:42am on Thursday 19th of June, 2025 AEST
•
Healthcare
Read Story
Amplia Therapeutics Scores Rare Second Complete Response in Pancreatic Cancer Trial
8:42am on Thursday 19th of June, 2025 AEST
Key Points
Second confirmed complete response in ACCENT trial
Narmafotinib combined with chemotherapy shows promising activity
Complete responses are exceptionally rare in advanced pancreatic cancer
Trial conducted across Australia and South Korea
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Amplia Therapeutics (ASX:ATX)
OPEN ARTICLE